List of Excipients in Branded Drug INVOKAMET

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Janssen Pharmaceuticals Inc	INVOKAMET	canagliflozin and metformin hydrochloride	50458-540	CELLULOSE, MICROCRYSTALLINE	2030-07-06
Janssen Pharmaceuticals Inc	INVOKAMET	canagliflozin and metformin hydrochloride	50458-540	CROSCARMELLOSE SODIUM	2030-07-06
Janssen Pharmaceuticals Inc	INVOKAMET	canagliflozin and metformin hydrochloride	50458-540	HYPROMELLOSE	2030-07-06
Janssen Pharmaceuticals Inc	INVOKAMET	canagliflozin and metformin hydrochloride	50458-540	MAGNESIUM STEARATE	2030-07-06
Janssen Pharmaceuticals Inc	INVOKAMET	canagliflozin and metformin hydrochloride	50458-540	POLYETHYLENE GLYCOL 3350	2030-07-06
Janssen Pharmaceuticals Inc	INVOKAMET	canagliflozin and metformin hydrochloride	50458-540	POLYVINYL ALCOHOL	2030-07-06
Janssen Pharmaceuticals Inc	INVOKAMET	canagliflozin and metformin hydrochloride	50458-540	TALC	2030-07-06

Invokamet Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Invokamet is a fixed-dose oral combination of canagliflozin and metformin hydrochloride marketed by Janssen Pharmaceuticals. Its commercial value is concentrated in formulation execution rather than active-ingredient differentiation. The strongest opportunities are generic or authorized-generic development, excipient optimization for immediate-release and extended-release products, supply-chain substitution, and lifecycle reformulation.

Invokamet has two principal products:

Product	Active ingredients	Dosage form	FDA application
Invokamet	Canagliflozin/metformin hydrochloride	Immediate-release tablet	NDA 204353
Invokamet XR	Canagliflozin/metformin hydrochloride	Extended-release tablet	NDA 205879

Invokamet was approved in 2014. Invokamet XR followed in 2016. Both products are indicated as an adjunct to diet and exercise for adults with type 2 diabetes mellitus. The products are not biologics, so biosimilar regulation does not apply. Competitive entry proceeds through the abbreviated new drug application, or ANDA, pathway.[1][2]

What excipients are used in Invokamet and Invokamet XR?

Invokamet uses conventional oral solid-dose excipients, but the combination creates formulation constraints because canagliflozin and metformin have different dose, solubility, and release requirements.

Invokamet immediate-release formulation

The immediate-release product uses excipient classes associated with:

• Tablet binding and mechanical strength
• Disintegration
• Flow and content uniformity
• Lubrication
• Film coating
• Color identification

The FDA-approved labeling identifies excipients including microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, and coating components such as polyethylene glycol, talc, titanium dioxide, and iron oxides.[1]

The formulation challenge is the high metformin load. Metformin hydrochloride is commonly administered at gram-level daily doses, while canagliflozin is administered at substantially lower strengths. A fixed-dose tablet must maintain dose uniformity for canagliflozin without creating an excessively large or fragile tablet.

Invokamet XR formulation

Invokamet XR uses a modified-release architecture designed to control metformin release while preserving canagliflozin exposure. The extended-release formulation relies on hydrophilic polymer technology, with hypromellose-type materials playing a central role in matrix formation and release control.[2]

Key formulation variables include:

• Polymer grade and viscosity
• Polymer concentration
• Granulation method
• Compression force
• Tablet porosity
• Coating weight
• Particle-size distribution
• Dissolution behavior across pH conditions

The XR product is more difficult to replicate than the immediate-release product because a generic manufacturer must demonstrate both pharmaceutical equivalence and comparable release behavior. A formulation that matches the listed excipients but fails dissolution similarity can still face regulatory rejection.

How does excipient selection affect Invokamet generic development?

Excipient selection affects four commercial requirements: bioequivalence, dissolution, manufacturing reliability, and supply continuity.

Bioequivalence risk

The most important risk is that excipient changes alter the absorption profile of metformin or the exposure relationship between metformin and canagliflozin. This is particularly relevant to Invokamet XR, where polymer selection can change:

• Initial release
• Midpoint release
• Total release duration
• Food effect
• Dose dumping risk
• Intertablet variability

A generic developer should treat the release-controlling polymer as a critical material attribute rather than a commodity ingredient.

Manufacturing risk

Metformin hydrochloride has high loading and can create problems with:

• Poor powder flow
• Segregation
• Sticking and picking
• High compression-force requirements
• Capping and lamination
• Tablet weight variability

Direct compression may be commercially attractive but can be less robust when the active blend has poor flow or compressibility. Wet granulation can improve uniformity and tablet strength, but it adds process steps, drying costs, and potential stability risks.

Excipient compatibility

Canagliflozin and metformin must remain chemically and physically stable during granulation, compression, coating, and storage. Compatibility screening should assess:

• Moisture exposure
• Oxidative degradation
• Interaction with alkaline or acidic excipients
• Polymer-active interactions
• Lubricant overmixing
• Coating-induced moisture transfer

Magnesium stearate concentration and mixing time require particular control because excessive lubrication can reduce tablet tensile strength and slow dissolution.

What excipient strategies offer the best commercial opportunities?

The highest-value strategies are those that improve manufacturability without changing the product’s therapeutic positioning.

1. High-load tablet engineering

A developer can reduce tablet size and improve robustness through:

• High-density metformin granules
• Optimized particle-size distribution
• Co-processed excipients
• Improved roller compaction
• Lower lubricant loading
• Higher-efficiency binders

A smaller, stronger tablet can reduce packaging volume, shipping costs, and patient burden. These benefits may support differentiation in tender markets and pharmacy substitution, even when the product is therapeutically equivalent.

2. Extended-release polymer optimization

For Invokamet XR, polymer engineering is the most important technical opportunity. Potential approaches include:

• Combining different hypromellose viscosity grades
• Using a polymer blend to flatten the release curve
• Adjusting matrix porosity
• Modifying granule size
• Using a barrier or functional coating
• Improving robustness against food-related dissolution changes

The commercial objective is not merely to match the reference dissolution profile. A robust formulation should remain within specification after scale-up, transport, aging, and normal manufacturing variation.

3. Excipient substitution and dual sourcing

A generic manufacturer can reduce supply-chain exposure by qualifying alternative suppliers for:

• Microcrystalline cellulose
• Hypromellose
• Croscarmellose sodium
• Magnesium stearate
• Film-coating systems
• Iron oxide colorants

Supplier substitution must be managed through comparability testing and change-control procedures. The highest-risk substitutions involve the release-controlling polymer, disintegrant grade, and high-density filler because small differences in particle morphology or substitution level can affect dissolution.

4. Lower-cost coating systems

Film coating is unlikely to provide meaningful patent differentiation by itself, but it can reduce manufacturing cost. Opportunities include:

• Lower coating weight
• Aqueous coating systems
• Standardized premixed coating platforms
• Reduced titanium dioxide use
• Colorant simplification
• Faster pan-coating cycles

Color matching remains commercially relevant because branded and generic tablets must be distinguishable while maintaining acceptable appearance and identification.

5. Patient-focused formulation design

Potential lifecycle products could target:

• Smaller tablets
• Improved swallowability
• Reduced tablet count
• Alternative strengths
• More consistent release with meals
• Reduced gastrointestinal intolerance from metformin exposure

These opportunities require evidence that the formulation provides a meaningful clinical or adherence advantage. Excipients alone are unlikely to support a new indication or broad regulatory exclusivity.

What patents protect Invokamet and its formulation?

Invokamet protection is based primarily on patents covering canagliflozin, combination therapy, dosage forms, and extended-release delivery. The exact Orange Book listing must be reviewed against the current FDA publication because listed patents and delisting events can change over time.[3]

Protection category	Commercial relevance	Typical challenge
Canagliflozin compound patents	Protect the active pharmaceutical ingredient	Paragraph IV invalidity or non-infringement challenge
Canagliflozin/metformin combination patents	Cover coadministration or fixed-dose combinations	Claim construction and obviousness challenge
Extended-release formulation patents	Protect Invokamet XR release architecture	Formulation non-infringement and invalidity challenge
Method-of-use patents	Cover treatment of type 2 diabetes or related dosing methods	Section viii statement or carve-out
Manufacturing patents	Cover synthesis, purification, or crystallization	Process substitution and non-infringement
Regulatory exclusivity	Delays certain ANDA approvals independently of patent rights	Expiration by statutory period

Excipient composition alone is usually a weak patent position unless the claims tie the excipient system to a defined release profile, dissolution range, stability result, or manufacturing process. A claim directed only to a familiar tablet excipient is vulnerable to novelty and obviousness attacks.

Paragraph IV challenges

An ANDA applicant may file a Paragraph IV certification alleging that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed. The first qualifying Paragraph IV filer may become eligible for 180-day generic exclusivity, subject to statutory requirements and forfeiture provisions.[4]

For Invokamet, the commercial importance of a Paragraph IV filing depends on:

• Which listed patent is challenged
• Whether the patent covers immediate-release or XR product
• Whether the applicant can use a section viii carve-out
• Whether the patent owner files suit within 45 days
• Whether a 30-month stay applies
• Whether multiple applicants share first-filer status
• Whether settlement delays or limits launch

A generic applicant pursuing the XR product faces a greater technical burden because it must address modified-release equivalence, not simply active-ingredient identity.

When does Invokamet lose exclusivity?

Invokamet does not have a single exclusivity date. Market entry depends on the interaction of:

1. FDA regulatory exclusivity.
2. Orange Book-listed patents.
3. Patent-term adjustments and extensions.
4. Pediatric exclusivity.
5. Litigation stays.
6. Settlement agreements.
7. ANDA approval timing.

The active-ingredient exclusivity period is distinct from patent protection. Canagliflozin’s principal composition-of-matter protection has been a central barrier to generic entry, while later combination and formulation patents can create additional barriers. Generic applicants therefore evaluate the product through a patent-by-patent claim chart rather than relying on a single expiration date.

The relevant regulatory framework is:

Issue	Rule
ANDA patent certification	Paragraph I, II, III, IV, or section viii statement
Paragraph IV notice	Sent to the NDA holder and patent owner
Litigation stay	Can delay approval for up to 30 months if suit is timely filed
First-filer incentive	Potential 180-day exclusivity
Label carve-out	Permits approval for non-patented uses when legally available
Pediatric extension	Can add six months to certain exclusivity or patent periods

The FDA Orange Book remains the controlling source for currently listed patents and expiration information.[3]

What FDA regulatory issues affect Invokamet generic entry?

A generic Invokamet developer must establish pharmaceutical equivalence and bioequivalence. The regulatory package normally addresses:

• Same active ingredients
• Same strengths
• Same dosage form
• Same route of administration
• Comparable labeling, subject to permitted carve-outs
• Inactive-ingredient safety
• Dissolution similarity
• Stability
• Manufacturing controls
• Bioequivalence

For Invokamet XR, in vitro dissolution is especially important. The applicant may need comparative studies under multiple pH conditions and, depending on FDA requirements, pharmacokinetic studies under fed and fasted conditions.

The inactive-ingredient strategy must comply with FDA inactive-ingredient expectations. A new excipient, unusually high level, or novel route of administration can trigger additional review. Using excipients with established oral use and documented regulatory precedent reduces review risk.[5]

What manufacturing and intellectual-property barriers remain?

The main barriers are technical rather than proprietary.

Manufacturing barriers

• High metformin loading
• XR matrix reproducibility
• Tablet size and swallowability
• Low-dose canagliflozin uniformity
• Compression defects
• Dissolution drift after scale-up
• Film-coating consistency
• Supplier variability

Intellectual-property barriers

• Canagliflozin composition claims
• Fixed-dose combination claims
• XR matrix or release-profile claims
• Dosing claims
• Crystalline-form or polymorph claims
• Manufacturing-process claims

A non-infringing generic can use different excipients, a different granulation route, or a different release-control system. The key is whether the alternative process and formulation avoid the asserted claim limitations while producing an equivalent product.

How strong is the Invokamet patent estate?

The estate is strongest where claims are tied to the canagliflozin molecule or a specific, technically defined release system. It is weaker where claims rely on broad combinations of conventional oral excipients without a demonstrated functional limitation.

Patent strategy	Relative strength	Reason
Compound claim for canagliflozin	High during enforceable term	Directly blocks use of the active ingredient
Narrow XR release-profile claim	Medium to high	Can block technically similar formulations
Broad fixed-dose combination claim	Medium	Vulnerable to obviousness and written-description arguments
Conventional excipient composition	Low to medium	Common excipients are readily substituted
Manufacturing-process claim	Variable	Strength depends on process-specific evidence
Method-of-use claim	Variable	May be avoidable through labeling carve-out

The practical strength of the estate depends on claim scope, remaining patent term, litigation history, and whether a generic can design around the claimed excipient or process limitations.

Which companies are likely to pursue Invokamet generic opportunities?

The most likely entrants are established generic manufacturers with:

• Oral solid-dose scale
• Modified-release development capability
• Existing metformin manufacturing
• Canagliflozin sourcing or synthesis capability
• ANDA litigation resources
• Commercial access to diabetes formularies

Potential business models include:

1. Independent ANDA development.
2. Licensing from a formulation specialist.
3. Contract development and manufacturing.
4. Authorized-generic supply.
5. Regional licensing outside the United States.
6. Portfolio bundling with other diabetes products.

The key competitive advantage is likely to be launch timing and cost of goods rather than a novel excipient. A company that can produce Invokamet XR with stable dissolution and low tablet-failure rates may have a stronger commercial position than a company with a nominally lower ingredient cost but weaker process capability.

What revenue exposure does Invokamet create?

Revenue exposure is determined by the combined sales of Invokana, Invokamet, and Invokamet XR, rather than Invokamet alone. The products compete within the broader SGLT2 inhibitor market, where canagliflozin faces Jardiance, Farxiga, and combination-product competition.

Generic entry can affect:

• Net price
• Formulary placement
• Rebates
• Prescriber retention
• Pharmacy substitution
• Combination-product switching
• Revenue from the broader canagliflozin franchise

The immediate-release product generally presents a lower technical barrier than the XR product. XR products can preserve a higher price differential if the reference formulation retains prescribing or formulary support, but generic entry can still compress pricing rapidly once multiple ANDA approvals occur.

What licensing opportunities exist around Invokamet excipients?

Licensing opportunities are strongest in technology that solves a defined manufacturing or regulatory problem:

• High-load metformin granulation
• Modified-release polymer systems
• Low-variability dissolution
• Tablet-size reduction
• Moisture-resistant coating
• Continuous manufacturing
• Co-processed filler-binder systems
• Supplier-qualified excipient platforms

A licensing package is more valuable when it includes formulation composition, process parameters, analytical methods, scale-up data, and freedom-to-operate analysis. A generic excipient mixture without comparative dissolution and stability data has limited licensing value.

How does Invokamet compare with competing diabetes combinations?

Product category	Primary formulation issue	Generic opportunity
Invokamet	Canagliflozin plus high-load metformin	Immediate-release and XR fixed-dose combinations
Empagliflozin/metformin	Similar high-load combination	Strong parallel opportunity
Dapagliflozin/metformin XR	Modified-release metformin with SGLT2 inhibitor	Higher release-control burden
Metformin monotherapy	High dose and gastrointestinal tolerability	Mature, price-driven market
SGLT2 monotherapy	Lower tablet mass	Simpler formulation, active-ingredient patent risk

Invokamet’s main technical differentiator is the combination of a low-dose SGLT2 inhibitor with high-dose metformin in one tablet. Invokamet XR adds a second layer of complexity through controlled release.

Key Takeaways

• Invokamet contains canagliflozin and metformin hydrochloride; Invokamet XR adds a modified-release metformin architecture.
• The main excipient opportunities involve high-load tableting, polymer-controlled release, supplier substitution, and coating-cost reduction.
• XR formulation development is more technically demanding than immediate-release development.
• Excipient patents are strongest when linked to a defined release profile, stability result, or manufacturing process.
• Generic entry depends on Orange Book patents, Paragraph IV strategy, litigation stays, regulatory exclusivity, and possible settlements.
• Invokamet has no biosimilar pathway because it is an oral small-molecule product.
• The most commercially valuable licensing assets include robust XR polymer systems, high-load granulation, and scale-up data.
• The current Orange Book should be reviewed before making a launch, litigation, or licensing decision.

FAQs

Can a generic manufacturer use different excipients from Invokamet?

Yes. A generic manufacturer generally may use different inactive ingredients if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, safety, dissolution, stability, and labeling.

Is Invokamet XR harder to formulate than Invokamet?

Yes. Invokamet XR requires control of metformin release over time, making polymer selection, matrix structure, dissolution testing, and scale-up more significant than for the immediate-release product.

Can an excipient supplier patent an Invokamet replacement formulation?

Potentially, but the strongest claims would require a novel composition or a functional limitation such as a defined dissolution profile, improved stability, or manufacturing advantage. Conventional excipient substitutions alone are usually difficult to protect broadly.

Does metformin create a tablet-size problem in Invokamet?

Yes. Metformin’s high dose can increase tablet mass, reduce swallowability, and create compression and content-uniformity challenges. Granulation and high-density excipient systems can reduce these problems.

Can an Invokamet generic launch before every patent expires?

Potentially. A launch may occur after a successful Paragraph IV challenge, a settlement agreement, a non-infringement determination, a patent expiration, or approval with a permitted labeling carve-out. The specific pathway depends on the asserted patents and litigation outcome.

References

1. U.S. Food and Drug Administration. (2024). Invokamet: Prescribing information, NDA 204353.
2. U.S. Food and Drug Administration. (2024). Invokamet XR: Prescribing information, NDA 205879.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards.
5. U.S. Food and Drug Administration. (2019). Inactive ingredient database guidance and database.
6. U.S. Food and Drug Administration. (2023). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA.
7. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act, Pub. L. No. 98-417.